Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine.
Saved in:
| Title: | Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. |
|---|---|
| Authors: | Harkin, Andrew (AUTHOR), Shanahan, Eamonn (AUTHOR), Kelly, John P. (AUTHOR), Connor, Thomas J. (AUTHOR) |
| Source: | European Journal of Neuroscience. Aug2003, Vol. 18 Issue 4, p1021-1027. 0p. |
| Subjects: | Neurochemistry, Malondialdehyde, Fluoxetine, Antidepressants, Laboratory rats |
| Abstract: | Abstract The effect of prior exposure to methylenedioxyamphetamine (MDA) on behavioural and neurochemical responses to fluoxetine were assessed in a rat model of antidepressant action. MDA (7.5 mg/kg, i.p.) was administered to rats twice daily for 4 consecutive days, and 4 weeks later the behavioural effect of fluoxetine (5 or 20 mg/kg; i.p. × 3) was examined in the modified rat forced-swimming test. In addition, the ability of fluoxetine to reduce serotonin (5-HT) metabolism was measured as an index of its efficacy in inhibiting 5-HT reuptake in vivo . In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) produced a characteristic increase in swimming behaviour in the forced-swimming test. In contrast, fluoxetine-induced swimming was markedly attenuated in MDA-treated rats. MDA pretreatment resulted in 5-HT nerve terminal degeneration, indicated by reduced 5-HT and 5-HIAA concentrations in the frontal cortex, amygdala and hippocampus, and reduced [3 H]paroxetine binding in the frontal cortex. In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) decreased 5-HT metabolism (5-HIAA : 5-HT ratio) in the frontal cortex, amygdala and hippocampus. MDA pretreatment attenuated the ability of fluoxetine to reduce 5-HT metabolism in all brain regions examined. These findings are the first to demonstrate that prior exposure to the methylenedioxy-substituted amphetamine MDA results in diminished responsiveness to the antidepressant fluoxetine. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neuroscience is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 10593590 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Harkin%2C+Andrew%22">Harkin, Andrew</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shanahan%2C+Eamonn%22">Shanahan, Eamonn</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kelly%2C+John+P%2E%22">Kelly, John P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Connor%2C+Thomas+J%2E%22">Connor, Thomas J.</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neuroscience%22">European Journal of Neuroscience</searchLink>. Aug2003, Vol. 18 Issue 4, p1021-1027. 0p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Neurochemistry%22">Neurochemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Malondialdehyde%22">Malondialdehyde</searchLink><br /><searchLink fieldCode="DE" term="%22Fluoxetine%22">Fluoxetine</searchLink><br /><searchLink fieldCode="DE" term="%22Antidepressants%22">Antidepressants</searchLink><br /><searchLink fieldCode="DE" term="%22Laboratory+rats%22">Laboratory rats</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Abstract The effect of prior exposure to methylenedioxyamphetamine (MDA) on behavioural and neurochemical responses to fluoxetine were assessed in a rat model of antidepressant action. MDA (7.5 mg/kg, i.p.) was administered to rats twice daily for 4 consecutive days, and 4 weeks later the behavioural effect of fluoxetine (5 or 20 mg/kg; i.p. × 3) was examined in the modified rat forced-swimming test. In addition, the ability of fluoxetine to reduce serotonin (5-HT) metabolism was measured as an index of its efficacy in inhibiting 5-HT reuptake in vivo . In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) produced a characteristic increase in swimming behaviour in the forced-swimming test. In contrast, fluoxetine-induced swimming was markedly attenuated in MDA-treated rats. MDA pretreatment resulted in 5-HT nerve terminal degeneration, indicated by reduced 5-HT and 5-HIAA concentrations in the frontal cortex, amygdala and hippocampus, and reduced [3 H]paroxetine binding in the frontal cortex. In vehicle-treated rats, fluoxetine (5 and 20 mg/kg) decreased 5-HT metabolism (5-HIAA : 5-HT ratio) in the frontal cortex, amygdala and hippocampus. MDA pretreatment attenuated the ability of fluoxetine to reduce 5-HT metabolism in all brain regions examined. These findings are the first to demonstrate that prior exposure to the methylenedioxy-substituted amphetamine MDA results in diminished responsiveness to the antidepressant fluoxetine. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of European Journal of Neuroscience is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=10593590 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1046/j.1460-9568.2003.02802.x Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 0 StartPage: 1021 Subjects: – SubjectFull: Neurochemistry Type: general – SubjectFull: Malondialdehyde Type: general – SubjectFull: Fluoxetine Type: general – SubjectFull: Antidepressants Type: general – SubjectFull: Laboratory rats Type: general Titles: – TitleFull: Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Harkin, Andrew – PersonEntity: Name: NameFull: Shanahan, Eamonn – PersonEntity: Name: NameFull: Kelly, John P. – PersonEntity: Name: NameFull: Connor, Thomas J. IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 08 Text: Aug2003 Type: published Y: 2003 Identifiers: – Type: issn-print Value: 0953816X Numbering: – Type: volume Value: 18 – Type: issue Value: 4 Titles: – TitleFull: European Journal of Neuroscience Type: main |
| ResultId | 1 |
